Intensive, long - term, early intervention support for children, young people and their families which may include: assessment and identification of needs; practical assistance and home - based support; linking with other relevant services; and,
targeted therapeutic groups.
Not exact matches
The work published in Cancer Cell complements previous research efforts from the CNIO Melanoma
Group, which could lead to the development of novel drugs that selectively
target the mechanism of cell autodigestion as a potential
therapeutic strategy.
University of Calgary researchers including Luchman, Weiss and Dr. Greg Cairncross — director of SACRI, and leader of the Terry Fox Research Institute (TFRI) «
Therapeutic Targeting of Glioblastoma research program at the university — are now working with cancer researchers Dr. Warren Mason (Princess Margaret Cancer Centre in Toronto) and Dr. Lesley Seymour (Director of the NCIC Clinical Trials
Group's Investigational New Drug Program), and drug manufacturer AstraZeneca, to plan a clinical trial testing a similar, but newer, drug related to AZD8055 (called AZD2014), in combination with TMZ, in patients with glioblastoma.
The study, led by ISGlobal — a centre supported by the «la Caixa» Foundation — and published in Scientific Reports, indicates that this enzyme could represent a selective
therapeutic target against this broad
group of parasites.
The authors, who are now planning to begin clinical trials based on this study, state that the three enzymes can be promising
therapeutic targets for a diverse and broad
group of DLBCL patients.
Furthermore, results may encourage other research
groups to use the M2 channel of influenza virus as
therapeutic target against the influenza A virus.
«We want to contribute to identifying new
targets of attack that could serve as a basis for the development of
therapeutic or diagnostic approaches,» explains
group leader Suttner.
The Research Training
Group «
Targets in Toxicology - Deciphering
Therapeutic Targets in Lung Toxicology» is a newly founded structured Ph.D. program which brings together twelve research partners in the Munich region in Germany.
Through strategic partnerships with industry and nonprofit organizations, we gain access to a portfolio of priority drugs for testing within our expert focus
groups, including checkpoint inhibitors,
therapeutic vaccines, innate immune stimulants,
targeted therapies, and many other promising treatments and technologies with high
therapeutic potential.
Our
group has 3 major goals: Develop novel
therapeutic approaches based on centrosomal clustering To further develop our first prototype inhibitors of centrosomal clustering preclinically and to establish a robust and specific high throughput small molecule screen Discover key events in myeloma pathogenesis To investigate the pivotal transition from the pre-malignant, asymptomatic to malignant, symptomatic stages of plasma cell dyscrasias in order to understand the pathophysiology and thereby identify novel
targets Translate small molecule therapeutics from bench to clinical trials To evaluate novel agents in the preclinical setting and to initiate early phase clinical trials in hematologic malignancies with focus on multiple myeloma
Wahl and his
group are striving to translate these studies to the clinic to help patients with breast cancers that currently lack
targeted therapeutic strategies.
The KITS Follow - Up study was a longitudinal study of the effects of an intervention that
targeted specific school - related skills during the summer and early fall preceding school entry via three mechanisms: (1) a
therapeutic playgroup; (2) caregiver psychoeducational support
groups; and (3) behavioral consultation in the home, school, and community settings.